Alzheimer's Disease: Neuroprogesterone, Epoxycholesterol, and ABC Transporters as Determinants of Neurodesmosterol Tissue Levels and its Role in Amyloid Protein Processing
Affiliations: Department of Medicine, NYU School of Medicine, New York, NY, USA
Correspondence:
[*]
Correspondence to: Norman B. Javitt, M.D., Ph.D., Department of Medicine, NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA. Tel.: +1 212 263 6588; Fax: +1 212 263 8282; E-mail: norman.javitt@med.nyu.edu.
Abstract: Evidence is emerging that during the development of Alzheimer's disease (AD), changes in the synthesis and metabolism of cholesterol and progesterone are occurring that may or may not affect the progression of the disease. The concept arose from the recognition that dehydrocholesterol 24-reductase (DHCR24/Seladin-1), one of the nine enzymes in the endoplasmic reticulum that determines the transformation of lanosterol to cholesterol, is selectively reduced in late AD. As a consequence, the tissue level of desmosterol increases, affecting the expression of ABC transporters and the structure of lipid rafts, both determinants of amyloid-β processing. However, the former effect is considered beneficial and the latter detrimental to processing. Other determinants of desmosterol tissue levels are 24,25 epoxycholesterol and the ABCG1 and ABCG4 transporters. Progesterone and its metabolites are determinants of tissue levels of desmosterol and several other sterol intermediates in cholesterol synthesis. Animal models indicate marked elevations in the tissue levels of these sterols at early time frames in the progression of neurodegenerative diseases. The low level of neuroprogesterone and metabolites in AD are consonant with the low level of desmosterol and may have a role in amyloid-β processing. The sparse data that has accumulated appears to be a sufficient basis for proposing a systematic evaluation of the biologic roles of sterol intermediates in the slowly progressive neurodegeneration characteristic of AD.
